(Total Views: 423)
Posted On: 10/03/2023 6:22:23 PM
Post# of 157788
Re: craigakess #137726
Agree I don’t think drug trials will ever go away anytime soon.
Also I don’t care about an AI partnership unless this would be used to further a partnership with BP and to get funding for bigger studies.
I believe this would be the case. ABSI was tasked with finding BP, aka ‘MRK’, 3 drugs to further develop their product portfolio. I believe Leronlimab to be one of them as noted by ABSI latest PR about HIV cure and Caltech. Caltech is actively working on a HIV cure and has patent with Leronlimab and CCR5 specifically.
MRK hopefully makes a deal with us if not already.
Edit*^
I should also mention per the last filing. We are still working actively on the cancer front. Just thought I’d remind all the shorts who said last CC cancer was dead because it wasn’t mentioned…..
Also I don’t care about an AI partnership unless this would be used to further a partnership with BP and to get funding for bigger studies.
I believe this would be the case. ABSI was tasked with finding BP, aka ‘MRK’, 3 drugs to further develop their product portfolio. I believe Leronlimab to be one of them as noted by ABSI latest PR about HIV cure and Caltech. Caltech is actively working on a HIV cure and has patent with Leronlimab and CCR5 specifically.
MRK hopefully makes a deal with us if not already.
Edit*^
I should also mention per the last filing. We are still working actively on the cancer front. Just thought I’d remind all the shorts who said last CC cancer was dead because it wasn’t mentioned…..
(4)
(0)
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
